[1]陈双,杨涛,顾愹.1型糖尿病的诊断与免疫治疗[J].国际内分泌代谢杂志,2021,41(06):578-582.[doi:10.3760/cma.j.cn121383-20210915-09046]
 Chen Shuang,Yang Tao,Gu Yong..Diagnosis and immunotherapy of type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2021,41(06):578-582.[doi:10.3760/cma.j.cn121383-20210915-09046]
点击复制

1型糖尿病的诊断与免疫治疗()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年06期
页码:
578-582
栏目:
专家论坛
出版日期:
2021-12-20

文章信息/Info

Title:
Diagnosis and immunotherapy of type 1 diabetes mellitus
作者:
陈双杨涛顾愹
南京医科大学第一附属医院内分泌科 210029
Author(s):
Chen Shuang Yang Tao Gu Yong.
Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
关键词:
1型糖尿病 诊断 免疫治疗
Keywords:
Type 1 diabetes mellitus Diagnosis Immunotherapy
DOI:
10.3760/cma.j.cn121383-20210915-09046
摘要:
1型糖尿病(T1DM)是T细胞介导的胰岛β细胞破坏的慢性自身免疫性疾病,表现为胰岛素依赖性的糖代谢紊乱。目前国内外关于T1DM的诊断仍没有统一的标准。胰岛素替代治疗仍然是T1DM治疗的必要手段,免疫治疗是近30年来研究者们尝试预防和逆转T1DM的方法,包括抗原特异性免疫治疗和非特异性免疫治疗,尽管其在延缓T1DM患者胰岛功能减退方面表现出一定程度的有效性,但尚无突破性的进展,本文将从最新的研究数据总结目前T1DM诊断和免疫治疗的相关进展。
Abstract:
Type 1 diabetes mellitus(T1DM)is a T-cell mediated autoimmune disease that directly damayes the pancreatic islet β-cells which resulting insulin deficiency and resultant hyperglycaemia. However,the diagnostic criteria for T1DM vary domestically and internationally. Insulin replacement is still the gold standard for the treatment of patients with T1DM. Over the past three decades, immune intervention has been conducted to prevent or reverse T1DM including antigen-specific immunotherapy and non-specific immunotherapy. Although it delays the decline of islet function to a certain extent, but no breakthrough has been achieved. This article summarizes the progress of diagnosis and immunotherapy of T1DM based on the latest research data.

参考文献/References:

[1] Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.National Diabetes Data Group[J].Diabetes,1979,28(12):1039-1057.DOI:10.2337/diab.28.12.1039.
[2] Insel RA,Dunne JL,Atkinson MA,et al.Staging presymptomatic type 1 diabetes:a scientific statement of JDRF,the Endocrine Society,and the American Diabetes Association[J].Diabetes Care,2015,38(10):1964-1974.DOI:10.2337/dc15-1419.
[3] DiMeglio LA,Evans-Molina C,Oram RA.Type 1 diabetes[J].Lancet,2018,391(10138):2449-2462.DOI:10.1016/S0140-6736(18)31320-5.
[4] 黄干,杨涛,刘煜,等.中国胰岛自身抗体检测标准化计划报告:检测方法调查及准确性评估[J].中华糖尿病杂志,2016,8(12):723-728.DOI:10.3760/cma.j.issn.1674.5809.2016.12.005.
[5] 陈恒,沈敏,戴皓,等.锌转运体8自身抗体电化学发光法的建立与应用[J].中华糖尿病杂志,2020,12(8):613-618.DOI:10.3760/cma.j.cn115791-20200429-00255.
[6] Gu Y,Jia X,Vartak T,et al.Improving clinical utility of GAD65 autoantibodies by electrochemiluminescence assay and clinical phenotype when identifying autoimmune adult-onset diabetes[J].Diabetologia,2021,64(9):2052-2060.DOI:10.1007/s00125-021-05492-6.
[7] Mallone R,Martinuzzi E,Blancou P,et al.CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes[J].Diabetes,2007,56(3):613-621.DOI:10.2337/db06-1419.
[8] Pociot F,Lernmark A.Genetic risk factors for type 1 diabetes[J].Lancet,2016,387(10035):2331-2339.DOI:10.1016/S0140-6736(16)30582-7.
[9] Luo S,Lin J,Xie Z,et al.HLA genetic discrepancy between latent autoimmune diabetes in adults and type 1 diabetes:LADA China study No.6[J].J Clin Endocrinol Metab,2016,101(4):1693-1700.DOI:10.1210/jc.2015-3771.
[10] Zhu M,Xu K,Chen Y,et al.Identification of novel T1D risk loci and their association with age and islet function at diagnosis in autoantibody-positive T1D individuals:based on a two-stage genome-wide association study[J].Diabetes Care,2019,42(8):1414-1421.DOI:10.2337/dc18-2023.
[11] Steffes MW,Sibley S,Jackson M,et al.Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial[J].Diabetes Care,2003,26(3):832-836.DOI:10.2337/diacare.26.3.832.
[12] Ludvigsson J,Carlsson A,Forsander G,et al.C-peptide in the classification of diabetes in children and adolescents[J].Pediatr Diabetes,2012,13(1):45-50.DOI:10.1111/j.1399-5448.2011.00807.x.
[13] Jones AG,Hattersley AT.The clinical utility of C-peptide measurement in the care of patients with diabetes[J].Diabet Med,2013,30(7):803-817.DOI:10.1111/dme.12159.
[14] Shields BM,Peters JL,Cooper C,et al.Can clinical features be used to differentiate type 1 from type 2 diabetes? a systematic review of the literature[J].BMJ Open,2015,5(11):e9088.DOI:10.1136/bmjopen-2015-009088.
[15] Cho MJ,Kim MS,Kim CJ,et al.Fasting serum C-peptide is useful for initial classification of diabetes mellitus in children and adolescents[J].Ann Pediatr Endocrinol Metab,2014,19(2):80-85.DOI:10.6065/apem.2014.19.2.80.
[16] 陈双,付麒,顾愹,等.1型糖尿病临床诊断模型的建立[J].中华糖尿病杂志,2016,8(10):598-602.DOI:10.3760/cma.j.issn.1674-5809.2016.10.006.
[17] Diabetes Prevention Trial--Type 1 Diabetes Study Group.Effects of insulin in relatives of patients with type 1 diabetes mellitus[J].N Engl J Med,2002,346(22):1685-1691.DOI:10.1056/NEJMoa012350.
[18] Skyler JS,Krischer JP,Wolfsdorf J,et al.Effects of oral insulin in relatives of patients with type 1 diabetes:the diabetes prevention trial--type 1[J].Diabetes Care,2005,28(5):1068-1076.DOI:10.2337/diacare.28.5.1068.
[19] Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group.Krischer JP,Schatz DA,Bundy B,et al.Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes:a randomized clinical trial[J].JAMA,2017,318(19):1891-1902.DOI:10.1001/jama.2017.17070.
[20] Alhadj AM,Liu YF,Arif S,et al.Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes[J].Sci Transl Med,2017,9(402).DOI:10.1126/scitranslmed.aaf7779.
[21] Rodriguez-Fernandez S,Almenara-Fuentes L,Perna-Barrull D,et al.A century later,still fighting back:antigen-specific immunotherapies for type 1 diabetes[J].Immunol Cell Biol,2021,99(5):461-474.DOI:10.1111/imcb.12439.
[22] Pescovitz MD,Greenbaum CJ,Bundy B,et al.B-lymphocyte depletion with rituximab and β-cell function:two-year results[J].Diabetes Care,2014,37(2):453-459.DOI:10.2337/dc13-0626.
[23] Orban T,Bundy B,Becker DJ,et al.Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes:follow-up 1 year after cessation of treatment[J].Diabetes Care,2014,37(4):1069-1075.DOI:10.2337/dc13-0604.
[24] Herold KC,Bundy BN,Long SA,et al.An anti-CD3 antibody,teplizumab,in relatives at risk for type 1 diabetes[J].N Engl J Med,2019,381(7):603-613.DOI:10.1056/NEJMoa1902226.
[25] Keymeulen B,van Maurik A,Inman D,et al.A randomised,single-blind,placebo-controlled,dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes[J].Diabetologia,2021,64(2):313-324.DOI:10.1007/s00125-020-05317-y.
[26] Rigby MR,Harris KM,Pinckney A,et al.Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients[J].J Clin Invest,2015,125(8):3285-3296.DOI:10.1172/JCI81722.
[27] Haller MJ,Schatz DA,Skyler JS,et al.Low-dose anti-thymocyte globulin(ATG)preserves β-Cell function and improves HbA1c in new-onset type 1 diabetes[J].Diabetes Care,2018,41(9):1917-1925.DOI:10.2337/dc18-0494.

相似文献/References:

[1]袁扬,孙子林.PANDER与β细胞凋亡[J].国际内分泌代谢杂志,2007,(04):253.
[2]孙敏讷,段宇.老年亚临床甲状腺功能减退症的诊治特点[J].国际内分泌代谢杂志,2014,(06):411.[doi:10.3760/cma.j.issn.1673-4157.2014.06.014]
 Sun Minne,Duan Yu..Diagnositc and therapeutic characteristics of subclinical hypothyroidism in elderly people[J].International Journal of Endocrinology and Metabolism,2014,(06):411.[doi:10.3760/cma.j.issn.1673-4157.2014.06.014]
[3]胡欣 陈国芳 刘超.男性迟发型性腺功能减退症的诊断与治疗[J].国际内分泌代谢杂志,2015,(01):59.[doi:10.3760/cma.j.issn.1673-4157.2015.01.015]
 Hu Xin,Chen Guofang,Liu Chao..Diagnosis and therapeutic options for late-onset hypogonadism in men[J].International Journal of Endocrinology and Metabolism,2015,(06):59.[doi:10.3760/cma.j.issn.1673-4157.2015.01.015]
[4]刘媛 刘超.1型糖尿病青少年儿童心理行为问题研究进展[J].国际内分泌代谢杂志,2015,(01):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
 Liu Yuan,Liu Chao..Psychological problems in adolescents and children with type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(06):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
[5]王思倩,吴锦丹.肠促胰素对1型糖尿病患者血糖及胰岛功能的影响[J].国际内分泌代谢杂志,2015,(03):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
 Wang Siqian,Wu Jindan..Effects of incretin on blood glucose and islet function in type 1 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(06):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
[6]李亚兰,项洁,卜瑞芳.1型糖尿病的DiaPep277免疫治疗[J].国际内分泌代谢杂志,2014,(03):169.[doi:10.3760/cma.j.issn.1673-4157.2014.03.007]
 Li Yalan,Xiang Jie,Bu Ruifang..Immunotherapy with DiaPep277 peptide in type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2014,(06):169.[doi:10.3760/cma.j.issn.1673-4157.2014.03.007]
[7]陈晔,李艳玲,王坚.天然免疫细胞在1型糖尿病中的作用[J].国际内分泌代谢杂志,2014,(03):184.[doi:10.3760/cma.j.issn.1673-4157.2014.03.011]
 Chen Ye,Li Yanling,Wang Jian..Role of innate immune cells in type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2014,(06):184.[doi:10.3760/cma.j.issn.1673-4157.2014.03.011]
[8]刘晓蓉 朱德发.糖尿病下肢动脉病变的诊断与治疗[J].国际内分泌代谢杂志,2015,(05):327.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.010]
 Liu Xiaorong*,Zhu Defa..Diagnosis and treatment of lower extremity arterial disease in diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):327.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.010]
[9]蔡芸莹 苏恒.1型糖尿病的非胰岛素治疗[J].国际内分泌代谢杂志,2015,(06):388.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.007]
 Cai Yunying,Su Heng.Noninsulin management in type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):388.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.007]
[10]曹琳,刘超.妊娠糖尿病诊疗的争议与共识[J].国际内分泌代谢杂志,2016,36(03):176.[doi:10.3760/cma.j.issn.1673-4157.2016.03.08]
 Cao Lin,Liu Chao..Controversy and concensus on the diagnosis and treatment of gestational diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(06):176.[doi:10.3760/cma.j.issn.1673-4157.2016.03.08]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81770777); 上海市医药卫生发展基金会糖尿病临床研究项目(Ⅰ期02研究); 南京医科大学第一附属医院(江苏省人民医院)优秀中青年人才支持计划
通信作者:顾愹,Email:yong.gu@njmu.edu.cn
更新日期/Last Update: 2021-12-10